Right now, GLP-1s get all the attention. But more and more research suggests that #amylin agonists might be the next big thing in #obesity and diabetes treatment. This bears watching.
conscienhealth.org/2026/03/25/f...

✨New issue✨

Check out the latest in #Metabolism research from across all disciplines. 🧪

Read about #AdiposeInnervation, #Amylin, #Cancer, #LiverMetabolism, #MitochondrialMetabolism, #Mycobiome, #Neurometabolism, #Redox, #T2D and many more topics!

www.nature.com/natmetab/vol...

Peripheral #amylin synergizes with #diabetes to impair lysosomal function, elevate #pTau in the #brain and pancreas, and accelerate #tauopathy, highlighting a pancreas–brain axis linking metabolic dysfunction to #neurodegeneration.

#OpenAccess: doi.org/10.1016/j.ge...

New review explores amylin receptor agonists (AMYRAs) as next generation therapies for obesity, offering benefits that go beyond weight loss. With advances in AMYR biology, dual agonism, and delivery tech, AMYRAs may redefine precision obesity care by 2030.
#ObesityResearch #MetabolicHealth #Amylin

Antibodies.com | Antibodies, Proteins, and ELISA Kits Antibodies.com supplies high-quality antibodies, proteins, and ELISA kits to life science researchers at cost-effective prices. Discover more, for less.

#Amylin is a hormone peptide oversecreted alongside insulin, forming #amyloid deposits in pancreatic β-cells and cerebral blood vessels of patients with comorbid T2D and dementia. Suggesting a pathological function of amylin in the brain.

Novel GLP-1-based Medications for Type 2 Diabetes and Obesity Abstract. The approvals of semaglutide and tirzepatide have set new benchmarks in the treatment of type 2 diabetes and obesity. Building on their success,

Novel GLP-1-based Medications for Type 2 Diabetes and Obesity. Read more in #JCEM: bit.ly/481iNV3 #Glucagon-Like-Peptide-1 #GLP-1 #amylin #obesity @endocrinesociety.bsky.social

Ozempic’s Latest Weight Loss Competition Is Like Nothing We’ve Seen Before In an early human trial, Eli Lilly's eloralintide helped people lose up to 20% of their body weight.

New review to read! Neuroendocrinology meets #addiction.

➡️ Emerging pharmacotherapies on the horizon
➡️ Special emphasis on glucagon-like peptide-1, ghrelin, fibroblast growth factor-21, amylin, glucocorticoids and mineralocorticoids.

🔗 doi.org/10.1111/joim.70021

#amylin #FGF-21

Amycretin delivers unprecedented weight loss in early trial for obesity treatment Once-weekly amycretin, a novel peptide activating GLP-1, amylin, and calcitonin receptors, produced rapid, substantial, and sustained weight loss in adults with overweight or obesity during a phase 1b...

Amycretin delivers unprecedented weight loss in early trial for obesity treatment www.news-medical.net/news/2025062... #Amycretin #Obesity #WeightLoss #GLP1 #Amylin #MetabolicHealth #ClinicalTrial #Innovation #Endocrinology #Health @thelancet.com

Yesterday, Metsera presented investors with topline data from phase one studies of a new #amylin analog for obesity that promises #MonthlyDosing. This is an early stage drug known only by its code name – #MET233i.
conscienhealth.org/2025/06/mets...

Amylin: From Mode of Action to Future Clinical Potential in Diabetes and Obesity Is amylin the missing piece of the puzzle when it comes to precision diabetology? Explore amylin’s diverse physiological functions and the evolution of amylin-based therapies, from key properties to…

Is #amylin the missing piece of the puzzle when it comes to precision #diabetology?

In this #EdsChoice review, explore amylin’s diverse physiological functions and the evolution of amylin-based therapies, from key properties to clinical significance.

👉 buff.ly/I2S0Sbp

#MedSky #Diabetes

Could amylin outshine GLP-1 in obesity? Incretin-based therapies have dominated the weight-loss Olympics, with companies chasing higher percentage losses like athletes chasing record-breaking sco...

With the #Roche and #Zealand deal for up to $5.3B for #amylin agonist #petrelintide in #obesity, re-upping my story from last week on the promise of amylin in #obesity: www.biocentury.com/article/655255

From the pancreas to the amygdala: New brain area critical for ingestive and motivated behavior control exerted by amylin Molecular biology; Neuroscience

🧠🍽️ #Amylin acts in the central amygdala (CeA) to regulate feeding & motivated behavior
We show that CeA amylin signaling is critical for appetite suppression, macronutrient selection & body weight control. Disrupting this pathway leads to hyperphagia & weight gain.

#Neuroskyence 🧪 #ObesityResearch

AbbVie and Gubra Announce License Agreement to Develop an Amylin Analog for the Treatment of Obesity Partnership marks AbbVie's entrance into the obesity field Agreement will enable the incorporation of GUB014295, an amylin peptide discovered and developed by Gubra, into AbbVie's global...

AbbVie enters the #obesity race with the licensing of Gubra’s long-acting #amylin peptide analog, GUB014295, currently in Phase 1

$350 million upfront and up to $1.9 billion in milestones

news.abbvie.com/2025-03-03-A...

More than a decade ago, targeting #amylin receptors for treating #obesity looked like hot opportunity. Now the idea is back and some are saying it could yield #BestInClass therapies.
HT: #ZealandPharma
conscienhealth.org/2025/02/the-...

Sex-specific signatures of GLP-1 and amylin on resting state brain activity and functional connectivity in awake rats Gut-produced glucagon-like peptide-1 (GLP-1) and pancreas-made amylin robustly reduce food intake by directly or indirectly affecting brain activity. …

🚨New study alert!
We used resting-state fMRI in rats to investigate the effects of GLP-1 and amylin on brain activity and functional connectivity. The results show sex-specific differences in neural responses ⬇️

#GLP1 #amylin #neuroskyence

Two years ago I went to the US as a visiting researcher during my PhD. Now our paper from one of the projects was accepted for publication 🎉 Hope to share it with you soon!!

#GLP1 #amylin